G.d. Searle & Company

Other

Abbott Laboratories Corporation

Abbvie Inc.

Pfizer Corporation

Metamateria Technologies LLC

Gary B Gordon

Jaime L Masferrer

John Patrick McKearn

Stephen T Gately

James J Cunningham

Alane T Koki

Karen Seibert

Thomas Edward Rogers

Steven Elmore

Peter Gerrard Ruminski

Saul H Rosenberg

Vincent L Giranda

Richard L Helferich

Mustafa Vurma

Debabrata Rautaray

Suvankar Sengupta

William F Westlin

Mark D McKee

G Allen Nickols

Jay Cunningham

Zeb F High, Jr

Jane Qian

Isiah Joseph

Qin Qin

Richard J Schorr

A self-sanitizing chair is shown and described. The chair may comprise a seating surface, legs, arm rest, head rest, and a sanitizing system. The latter may include a UV light source and a sanitizing fluid dispensing system. UV light and sanitizing fluid are applied to surfaces of the chair contacted by a human user. Indicating lights indicate when sanitizing is being performed, when sanitizing fluid is drying, and when the chair is ready for the next user. A control circuit operates the indicating lights and includes an occupant sensor. Sanitizing is inhibited in the presence of an occupant and commenced when the occupant has left the chair.

Modified and improved self-sanitizing chair

Methods of preparing a nutritional product which contain a lipophilic nutrient are disclosed. The nutritional product is made using a fortifying powder containing the lipophilic nutrient, a monoglyceride and diglyceride ('MDG') oil, a phospholipid, and a carrier. The fortifying powder enhances the digestive absorption of the lipophilic nutrient when the nutritional product is consumed. The fortifying powder simplifies the process of manufacturing the nutritional product, as the fortifying powder can be added at a suitable stage of the process with other powdered ingredients. The fortifying powder may be manufactured in bulk and stored for later use, thereby improving manufacturing efficiencies. The fortifying powder and methods of preparing the fortifying powder are also presented.

Nutritional products having improved lipophilic solubility and bioavailability in an easily mixable form

This invention pertains to a method for the treatment of non-small cell lung cancer in a subject who is a smoker, comprising administering to the subject an effective amount of 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (veliparib or ABT-888), or a pharmaceutically acceptable salt thereof, in combination with carboplatin and paclitaxel.

Veliparib in combination with carboplatin and paclitaxel for the treatment of non-small cell lung cancer in smokers

The invention relates to a method for the treatment of triple negative breast cancer in a subject, comprising administering to the subject an effective amount of 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide, or a pharmaceutically acceptable salt thereof, and an effective amount of carboplatin, in combination with standard of care.

Veliparib in combination with carboplatin for the treatment of triple negative breast cancer

Cement compositions and methods for making cement compositions are provided. The cement compositions can comprise at least one oxide having a particle size of less than about 600 nm. The methods for making cement may include: providing a mixture of compounds containing the required calcium, silicon, aluminum, and iron to provide at least one of tricalcium silicate, dicalcium silicate, tricalcium aluminate, tetracalcium aluminoferrite, other calcium silicates, aluminates, ferrites, and silicates or combinations thereof; adding a fuel source and an oxidizer to the mixture of compounds; and heating the mixture of compounds, the fuel source, and the oxidizer such that the mixture of compounds, the fuel source, and the oxidizer ignite to form the at least one tricalcium silicate, dicalcium silicate, tricalcium aluminate, and tetracalcium aluminoferrite, or combinations thereof.

Cement and methods of preparing cement

Methods of reducing the number of platelets in mammals and preventing or treating pro-thrombotic conditions and diseases that are characterized by an excess of, or undesired activation of, platelets using inhibitors of anti-apoptotic Bcl-2 family protein members is disclosed.

Treatment of myeoproliferative diseases

The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of a matrix metalloproteinase inhibitor and an antineoplastic agent.

Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent

A method of using an MMP inhibitor and optionally radiation therapy, and one or more antineoplastic agents of the topoisomerase class selected from the group consisting of irinotecan and topotecan, as a combination therapy for the treatment of neoplasia is disclosed.

Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia

The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of an integrin antagonist and an antineoplastic agent.

Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia

The present invention provides methods to treat neoplasia disorders in a mammal using a combination of radiation and an integrin antagonist.

Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia

Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia

&agr;&ngr;&bgr;3 integrin antagonists in combination with chemotherapeutic agents

This invention relates to the use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing and treating neoplasia. In particular, the invention describes the method of preventing and treating epithelial cell neoplasia in a subject, said method comprising treating the subject with a therapeutically-effective amount of a compound of Formula I. ##STR1## wherein A, R.sup.2 and R.sup.3 are as described in the specification.

Method of using cyclooxygenase-2 inhibitors in the treatment and

Growing community of inventors

Highland Park, IL, United States of America

Gary B Gordon